Hereditary Hemorrhagic Telangiectasia
1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
HELP TherapeuticsChina - Nanjing
1 programNationwide Awareness Campaign and Call for Dental Screening for HHT in GermanyN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
Alnylam PharmaceuticalsALN-6400
HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Clinical Trials (2)
Total enrollment: 120 patients across 2 trials
A Study to Evaluate ALN-6400 in Healthy Volunteers and Patients With Hereditary Hemorrhagic Telangiectasia (HHT)
Start: Nov 2024Est. completion: Jun 2028120 patients
Phase 1/2Recruiting
NCT03549949HELP TherapeuticsNationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Nationwide Awareness Campaign and Call for Dental Screening for HHT in Germany
Start: Jun 2018Est. completion: Jul 2022
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 120 patients
2 companies competing in this space